
| Code | Product | Strength | Indication | GMP | Registration |
|---|---|---|---|---|---|
| UB766 | Penpulimab Injection | 100mg(10ml)/bottle | Relapsed or refractory classical Hodgkin lymphoma; Locally advanced or metastatic squamous non-small cell lung cancer | CN - NMPA | China |
| UB763 | Bevacizumab Injection | 100mg(4ml)/bottle | Metastatic colorectal cancer; Advanced-stage non-small cell lung cancer; Metastatic non-small cell lung cancer; Recurrent non-small cell lung cancer; Recurrent glioblastoma; Epithelial ovarian cancer; Fallopian tube cancer; Primary peritoneal cancer; Cervical cancer; Hepatocellular carcinoma | CN - NMPA | China |
| UB762 | Rituximab Injection | 100mg(10ml)/bottle | Non-Hodgkin's lymphoma; Chronic lymphocytic leukaemia | CN - NMPA | China |
| UB761 | Trastuzumab Injection | 150 mg/bottle | Metastatic breast cancer; Early breast cancer; Metastatic gastric cancer | CN - NMPA | China |
| UB759 | Pertuzumab Injection | / | HER2 positive metastatic breast cancer | CN - NMPA | China |
| UB739 | Bevacizumab Injection | 40mg/0.8mL | Colorectal cancer; Lung cancer; Renal cancer; Cervical cancer; Ovarian cancer; Wet age-related macular degeneration | CN - NMPA | China |
| UB738 | Adalimumab Injection | 40mg/0.8mL | Rheumatoid arthritis; Ankylosing spondylitis; Psoriasis; Crohn's disease; Uveitis | CN - NMPA | China |
| UB654 | Trastuzumab injection | 150mg/vial | Breast cancer; Gastric cancer | CN - NMPA | China |
| UB653 | Tocilizumab injection | 80mg(4ml)/vial | Rheumatoid arthritis; Systemic juvenile idiopathic arthritis; Cytokine release syndrome | CN - NMPA | China |
| UB652 | Infliximab injection | 100mg/vial | Rheumatoid arthritis; Ankylosing spondylitis; Psoriasis; Crohn's disease; Ulcerative colitis | CN - NMPA; PIC/S | China |
| UB651 | Adalimumab Injection | 0.8ml: 40mg | Rheumatoid arthritis; Juvenile idiopathic arthritis; Ankylosing spondylitis; Psoriasis; Pediatric plaque psoriasis; Crohn's disease; Pediatric Crohn's disease; Uveitis | CN - NMPA; PIC/S; SA - SFDA | China; Saudi Arabia |
| UB492 | Trastuzumab | 150mg/vial | Breast cancer; Gastric cancer | CN - NMPA; EU - EMA | China |
| UB301 | Ustekinumab Injection | 0.5ml: 45mg | Plaque psoriasis; Crohn's disease | CN - NMPA | China |
| UB252 | Zuberitamab Injection | 100mg/10mL | Diffuse large B-cell lymphoma | CN - NMPA | China |
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →